+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Feasibility of the Less Is More Approach in Treating Low-Risk Ductal Carcinoma In Situ Diagnosed on Core Needle Biopsy: Ten-Year Review of Ductal Carcinoma In Situ Upgraded to Invasion at Surgery



Feasibility of the Less Is More Approach in Treating Low-Risk Ductal Carcinoma In Situ Diagnosed on Core Needle Biopsy: Ten-Year Review of Ductal Carcinoma In Situ Upgraded to Invasion at Surgery



Archives of Pathology and Laboratory Medicine 142(9): 1120-1126



Label="CONTEXT">- Ductal carcinoma in situ (DCIS) represents 20% of screen-detected breast cancers. The likelihood that certain types of DCIS are slow growing and may never progress to invasion suggests that our current standards of treating DCIS could result in overtreatment. The LORIS (LOw RISk DCIS) and LORD (LOw Risk DCIS) trials address these concerns by randomizing patients with low-risk DCIS to either active surveillance or conventional treatment.Label="OBJECTIVE">- To determine the upgrade rate of DCIS diagnosed on core needle biopsy to invasive carcinoma at surgery and to evaluate the safety of managing low-risk DCIS with surveillance alone, by characterizing the pathologic and clinical features of upgraded cases and applying criteria of the LORD and LORIS trials to these cases.Label="DESIGN">- A 10-year retrospective analysis of DCIS on core needle biopsy with subsequent surgery.Label="RESULTS">- We identified 1271 cases of DCIS on core needle biopsy: 200 (16%) low grade, 649 (51%) intermediate grade, and 422 (33%) high grade. Of the 1271 cases, we found an 8% upgrade rate to invasive carcinoma (n = 105). Nineteen of the 105 upgraded cases (18%) had positive lymph nodes. Low-grade DCIS was least likely to upgrade to invasion, comprising 10% (10 of 105) of upgraded cases. Three of the 105 upgraded cases (3%) met criteria for the LORD trial, and all were low-grade DCIS on core needle biopsy with favorable biology on follow-up.Label="CONCLUSIONS">- There is a clear risk of upgrade to invasion on follow-up excision; however, applying strict criteria of the LORD trial effectively decreases the likelihood of a missed invasive component or missed aggressive pathologic features.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 065149517

Download citation: RISBibTeXText

PMID: 29582675

DOI: 10.5858/arpa.2017-0268-oa


Related references

Predictors of invasion in patients with core-needle biopsy-diagnosed ductal carcinoma in situ and recommendations for a selective approach to sentinel lymph node biopsy in ductal carcinoma in situ. Cancer 107(8): 1760-1768, 2006

Risk of invasion and axillary lymph node metastasis in ductal carcinoma in situ diagnosed by core-needle biopsy. British Journal of Surgery 94(8): 952-956, 2007

Ductal carcinoma in situ diagnosed on core needle biopsy Predictors of invasion at follow-up. Modern Pathology 12(1): 30A, 1999

Ductal carcinoma in situ diagnosed with stereotactic core needle biopsy: can invasion be predicted?. Radiology 217(2): 466-470, 2000

The finding of invasive cancer after a preoperative diagnosis of ductal carcinoma-in-situ: causes of ductal carcinoma-in-situ underestimates with stereotactic 14-gauge needle biopsy. Annals of Surgical Oncology 10(7): 748-753, 2003

Lymphatic mapping of ductal carcinoma in situ diagnosed by stereotactic core needle biopsy. Journal of Clinical Oncology 24(18_Suppl): 10507-10507, 2016

Ductal carcinoma in situ and atypical ductal hyperplasia of the breast diagnosed at stereotactic core biopsy. Breast Journal 7(1): 14-18, 2001

Ductal carcinoma in situ diagnosed by breast needle biopsy: Predictors of invasion in the excision specimen. Breast 27: 15-21, 2016

Can mammographic findings help discriminate between atypical ductal hyperplasia and ductal carcinoma in situ after needle core biopsy?. Breast 17(3): 282-288, 2008

Factors associated with upstaging of ductal carcinoma in situ diagnosed by core needle biopsy using imaging guidance. Japanese Journal of Radiology 29(8): 547-553, 2011

A simple model to assess the probability of invasion in ductal carcinoma in situ of the breast diagnosed by needle biopsy. Biomed Research International 2014: 480840, 2014

Ductal carcinoma in situ and atypical ductal hyperplasia of the breast diagnosed at stereotaxic core neddle biopsy A multiinstitutional study. Virchows Archiv 435(3): 193, 1999

Borderline atypical ductal hyperplasia/low-grade ductal carcinoma in situ on breast needle core biopsy should be managed conservatively. American Journal of Surgical Pathology 37(6): 913-923, 2013

Lobular neoplasia in breast core needle biopsy specimens is not associated with an increased risk of ductal carcinoma in situ or invasive carcinoma. American Journal of Clinical Pathology 117(5): 797-799, 2002

Predicting invasion in the excision specimen from breast core needle biopsy specimens with only ductal carcinoma in situ. Archives of Pathology & Laboratory Medicine 126(1): 39-41, 2002